Cooper Companies (NASDAQ:COO) Releases Q4 2026 Earnings Guidance

Cooper Companies (NASDAQ:COO) issued an update on its fourth quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.050-1.090 for the period, compared to the consensus earnings per share estimate of 1.200. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Cooper Companies also updated its FY 2026 guidance to 4.510-4.550 EPS.

Wall Street Analyst Weigh In

Several brokerages recently commented on COO. KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a research report on Friday, June 5th. JPMorgan Chase & Co. cut their target price on shares of Cooper Companies from $71.00 to $58.00 and set a “neutral” rating for the company in a research note on Thursday. Weiss Ratings reiterated a “sell (d)” rating on shares of Cooper Companies in a report on Friday, September 4th. Wells Fargo & Company set a $61.00 target price on Cooper Companies and gave the stock an “equal weight” rating in a research note on Thursday. Finally, The Goldman Sachs Group set a $61.00 price target on Cooper Companies in a report on Wednesday, May 27th. Five equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $71.47.

Cooper Companies Stock Down 14.7%

COO stock opened at $54.17 on Friday. Cooper Companies has a fifty-two week low of $51.01 and a fifty-two week high of $89.83. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78. The stock has a market capitalization of $10.56 billion, a price-to-earnings ratio of 18.49, a PEG ratio of 1.66 and a beta of 0.82. The business’s fifty day moving average price is $72.02 and its two-hundred day moving average price is $69.81.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.92%. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same period in the prior year, the company posted $0.49 earnings per share. Cooper Companies’s revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities analysts anticipate that Cooper Companies will post 4.63 earnings per share for the current year.

Cooper Companies announced that its Board of Directors has initiated a share buyback program on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to reacquire up to 22.7% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper Companies reported fiscal third-quarter adjusted EPS of $1.15, above the roughly $1.11–$1.12 analyst consensus. Free cash flow increased 66% to $273 million, and the company repurchased $339.1 million of stock. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded its share-repurchase authorization from $2 billion to $3 billion, potentially allowing the company to buy back as much as 22.7% of outstanding shares. The authorization signals management’s belief that the stock is undervalued and could support per-share results. CooperCompanies Completes Strategic Review
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day days-to-cover ratio, indicating no meaningful short-interest signal; the figures may reflect incomplete or anomalous data.
• Negative Sentiment: Third-quarter revenue of approximately $1.07 billion missed the $1.10 billion consensus estimate. Management cited U.S. channel inventory reductions and destocking pressure affecting CooperVision and reduced its fiscal 2026 adjusted EPS outlook to $4.51–$4.55, below the $4.63 consensus. Fourth-quarter EPS guidance of $1.05–$1.09 also fell short of expectations. Why Cooper Stock Plunges After Earnings
• Negative Sentiment: Cooper completed its strategic review but decided not to sell or pursue a transaction for CooperSurgical. Investors appear disappointed because a sale could have unlocked value, while fertility-related litigation and competitive pressure from a new non-hormonal IUD add uncertainty. Cooper Cos. Stock Drops After Soft Outlook
• Negative Sentiment: Analysts lowered targets and ratings following the results: JPMorgan cut its target to $58 and UBS to $66, both with neutral ratings; William Blair downgraded the stock to market perform; and Robert W. Baird moved from strong buy to hold with a $61 target.
• Negative Sentiment: Law firms announced securities-fraud investigations concerning whether Cooper Companies adequately disclosed business conditions and the factors behind the outlook reduction, creating an additional overhang for investors. Securities Fraud Investigation Announcement

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Axxcess Wealth Management LLC lifted its holdings in shares of Cooper Companies by 37.1% during the 4th quarter. Axxcess Wealth Management LLC now owns 9,980 shares of the medical device company’s stock worth $818,000 after acquiring an additional 2,698 shares during the period. Corient Private Wealth LLC increased its stake in Cooper Companies by 17.0% in the fourth quarter. Corient Private Wealth LLC now owns 25,699 shares of the medical device company’s stock valued at $2,106,000 after acquiring an additional 3,738 shares during the last quarter. Alberta Investment Management Corp acquired a new position in Cooper Companies during the fourth quarter valued at approximately $1,582,000. Mercer Global Advisors Inc. ADV lifted its stake in Cooper Companies by 94.8% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 17,893 shares of the medical device company’s stock worth $1,466,000 after purchasing an additional 8,707 shares during the last quarter. Finally, Vident Advisory LLC lifted its stake in Cooper Companies by 476.6% during the fourth quarter. Vident Advisory LLC now owns 52,152 shares of the medical device company’s stock worth $4,274,000 after purchasing an additional 43,108 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.